Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases
ICI treatment is associated with a decreased risk of MBM development, suggesting a protective role. Elevated S100B levels and stage IV disease at advanced melanoma diagnosis might indicate an increased risk of MBM development.
Authors
- Matilda Samuelsson
- Roger Olofsson Bagge (ORCID: https://orcid.org/0000-0001-5795-0355)
- Lars Ny (ORCID: https://orcid.org/0000-0003-3864-5958)
- Max Levin (ORCID: https://orcid.org/0000-0001-9676-5582)
- Aldina Pivodic (ORCID: https://orcid.org/0000-0002-2224-3236)
- Henrik Jespersen (ORCID: https://orcid.org/0000-0002-6543-5369)
- Sara Bjursten (ORCID: https://orcid.org/0000-0001-6730-0188)
- Anna Fager (ORCID: https://orcid.org/0009-0003-6443-5345)
Institutions
- Oslo University Hospital (NO)
- Sahlgrenska University Hospital (SE)
- Swedish Society for Nature Conservation (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1038/s44276-025-00137-2
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Les Laboratories Pierre Fabre
- Syndax Pharmaceuticals
- SkylineDx
- Göteborgs Universitet
- Sanofi Genzyme